Skip to main content

Advertisement

SpringerLink
Log in

Sex differences in immune-related adverse events with immune checkpoint inhibitors: data mining of the FDA adverse event reporting system

  • Research Article
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background Although immune-related adverse events (irAEs) have been reported in patients receiving immune checkpoint inhibitor (ICI) therapy, sex differences in irAEs are not known. Aim The present study described, evaluated and compared differences in irAEs between females and males treated with ICIs. Method irAE reports were obtained from the FDA Adverse Event Reporting System (FAERS) from January 2004 to December 2020. Disproportionality analysis and Bayesian analysis were used to explore differences in irAEs between females and males. The onset time and fatality proportion of irAEs in different ICIs between females and males were further evaluated. Results A total of 30,342 irAE cases were obtained, including 11,097 female cases and 19,245 male cases. Consistent disproportionality signals were detected in females and males, including endocrine toxicity, hepatitis, lung toxicity, nervous system toxicity, and ocular toxicity. Renal toxicity was only detected in male patients receiving ICI therapy (PRR 2.37, 95% CI: 2.25–2.51; IC: 1.24, 95% CI: 1.05–1.43). Males had a longer onset time (females 35 days [IQR 14–87] vs. males 39 days [IQR 14–92], P = 0.041) and higher fatality proportion (females 20.5% vs. males 25.6%, P < 0.01). Conclusion This analysis revealed that males had a higher chance of exhibiting ICI-associated renal toxicity, longer median onset time and worse prognosis of irAEs than females. Greater attention to sex differences in ICI therapy is needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626–38.

    Article  CAS  Google Scholar 

  2. Triggianese P, Novelli L, Galdiero MR, et al. Immune checkpoint inhibitors-induced autoimmunity: The impact of gender. Autoimmun Rev. 2020; 19(8).

  3. Fish EN. The X-files in immunity: sex-based differences predispose immune responses. Nat Rev Immunol. 2008;8(9):737–44.

    Article  CAS  Google Scholar 

  4. Oertelt-Prigione S. The influence of sex and gender on the immune response. Autoimmun Rev. 2012;11(6–7):A479–85.

    Article  CAS  Google Scholar 

  5. Roberts CW, Walker W, Alexander J. Sex-associated hormones and immunity to protozoan parasites. Clin Microbiol Rev. 2001;14(3):476-+.

    Article  CAS  Google Scholar 

  6. Conforti F, Pala L, Bagnardi V, et al. Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis. Lancet Oncol. 2018;19(6):737–46.

    Article  CAS  Google Scholar 

  7. Wallis CJD, Butaney M, Satkunasivam R, et al. Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers A Systematic Review and Meta-analysis. JAMA Oncol. 2019;5(4):529–36.

    Article  Google Scholar 

  8. Conforti F, Pala L, Bagnardi V, et al. Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis. J Natl Cancer Inst. 2019;111(8):772–81.

    Article  Google Scholar 

  9. Wang S, Cowley LA, Liu X-S. Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy. J Natl Cancer Inst Molecules. 2019; 24(18).

  10. Duma N, Abdel-Ghani A, Yadav S, et al. Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal? Oncologist. 2019;24(11):E1148–55.

    Article  CAS  Google Scholar 

  11. Chen C, Wu B, Zhang C, et al. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system. Int Immunopharmacol. 2021; 95.

  12. Raschi E, Gatti M, Gelsomino F, et al. Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance. Target Oncol. 2020;15(4):449–66.

    Article  Google Scholar 

  13. Ye X, Hu F, Zhai Y, et al. Hematological toxicities in immune checkpoint inhibitors: A pharmacovigilance study from 2014 to 2019. Hematol Oncol. 2020;38(4):565–75.

    Article  CAS  Google Scholar 

  14. Thi Thu Ha N, Roussin A, Rousseau V, et al. Role of Serotonin Transporter in Antidepressant-Induced Diabetes Mellitus: A Pharmacoepidemiological-Pharmacodynamic Study in VigiBase((R)). Drug Saf. 2018;41(11):1087–96.

    Article  Google Scholar 

  15. Polanczyk MJ, Hopke C, Vandenbark AA, et al. Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of Treg cells, and enhanced expression of the PD-1 costimulatory pathway. J Neurosci Res. 2006;84(2):370–8.

    Article  CAS  Google Scholar 

  16. Polanczyk MJ, Hopke C, Vandenbark AA, et al. Treg suppressive activity involves estrogen-dependent expression of programmed death-1 (PD-1). Int Immunol. 2007;19(3):337–43.

    Article  CAS  Google Scholar 

  17. Carrero JJ, Hecking M, Chesnaye NC, et al. Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease. Nat Rev Nephrol. 2018;14(3):151–64.

    Article  Google Scholar 

  18. Hu R, Chen M, Xu Y, et al. Renal immune-related adverse events of immune checkpoint inhibitor. Asia Pac J Clin Oncol. 2020;16(6):305–11.

    Article  Google Scholar 

  19. Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11(2):141–51.

    Article  CAS  Google Scholar 

  20. Waeckerle-Men Y, Starke A, Wuethrich RP. PD-L1 partially protects renal tubular epithelial cells from the attack of CD8(+)cytotoxic T cells. Nephrol Dial Transplant. 2007;22(6):1527–36.

    Article  CAS  Google Scholar 

  21. Tivol EA, Borriello F, Schweitzer AN, et al LOSS OF CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3(5):541–7.

    Article  CAS  Google Scholar 

  22. Riella LV, Paterson AM, Sharpe AH, et al. Role of the PD-1 Pathway in the Immune Response. Am J Transplant. 2012;12(10):2575–87.

    Article  CAS  Google Scholar 

  23. Jaworska K, Ratajczak J, Huang L, et al. Both PD-1 Ligands Protect the Kidney from Ischemia Reperfusion Injury. J Immunol. 2015;194(1):325–33.

    Article  CAS  Google Scholar 

  24. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.

    Article  CAS  Google Scholar 

  25. Buchbinder EI, Desai A. CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol-Canc. 2016;39(1):98–106.

    Article  CAS  Google Scholar 

  26. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823–33.

    Article  CAS  Google Scholar 

  27. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(17):1627–39.

    Article  CAS  Google Scholar 

  28. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. N Engl J Med. 2011;364(26):2517–26.

    Article  CAS  Google Scholar 

  29. Lai L-T, Gu W-G, Hu M-B, et al. Sex-related differences in the efficacy of immune checkpoint inhibitors in malignancy: a systematic review and meta-analysis. Aging-Us. 2021;13(11):15413–32.

    Article  CAS  Google Scholar 

  30. Botticelli A, Onesti CE, Zizzari I, et al. The sexist behaviour of immune checkpoint inhibitors in cancer therapy? Oncotarget. 2017;8(59):99336–46.

    Article  Google Scholar 

  31. Schulz GB, Rodler S, Szabados B, et al. Safety, efficacy and prognostic impact of immune checkpoint inhibitors in older patients with genitourinary cancers. J Geriatr Oncol. 2020;11(7):1061–6.

    Article  Google Scholar 

  32. Corbaux P, Maillet D, Boespflug A, et al. Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting. Eur J Cancer. 2019;121:192–201.

    Article  CAS  Google Scholar 

  33. Elias R, Hartshorn K, Rahma O, et al. Aging, immune senescence, and immunotherapy: A comprehensive review. Semin Oncol. 2018;45(4):187–200.

    Article  Google Scholar 

  34. Cortazar FB, Marrone KA, Troxell ML, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016;90(3):638–47.

    Article  CAS  Google Scholar 

  35. Wanchoo R, Karam S, Uppal NN, et al. Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review. Am J Nephrol. 2017;45(2):160–9.

    Article  CAS  Google Scholar 

  36. Sise ME, Seethapathy H, Reynolds KL. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review. Oncologist. 2019;24(6):735–42.

    Article  Google Scholar 

  37. Zheng K, Qiu W, Wang H, et al. Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor-induced renal immune-related adverse events. Thorac Cancer. 2020;11(6):1746–51.

    Article  Google Scholar 

  38. Kumar V, Chaudhary N, Garg M, et al. Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. Front Pharmacol. 2017; 8.

  39. Chen G, Qin Y, Fan Q-Q, et al. Renal adverse effects following the use of different immune checkpoint inhibitor regimens: A real-world pharmacoepidemiology study of post-marketing surveillance data. Cancer Med. 2020;9(18):6576–85.

    Article  CAS  Google Scholar 

  40. Sakaeda T, Tamon A, Kadoyama K, et al. Data Mining of the Public Version of the FDA Adverse Event Reporting System. Int J Med Sci. 2013;10(7):796–803.

    Article  Google Scholar 

Download references

Acknowledgements

Not applicable.

Author information

Authors and Affiliations

  1. West China School of Pharmacy, Sichuan University, 610041, Chengdu, Sichuan, China

    Chen Chen, Chenyu Zhang, Ziyan Jin & Ting XU

  2. Department of Pharmacy, West China Hospital, Sichuan University Chengdu Sichuan, 610041, Chengdu, Sichuan, China

    Chen Chen, Chenyu Zhang, Ziyan Jin, Bin WU & Ting XU

Authors
  1. Chen Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chenyu Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ziyan Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bin WU
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ting XU
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Bin WU or Ting XU.

Ethics declarations

Funding

This study was supported by the National Key Research and Development Program of China (NO: 2020YFC2008302).

Conflicts of interest

The authors declare that they had no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic Supplementary Material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Supplementary Material 2

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, C., Zhang, C., Jin, Z. et al. Sex differences in immune-related adverse events with immune checkpoint inhibitors: data mining of the FDA adverse event reporting system. Int J Clin Pharm 44, 689–697 (2022). https://doi.org/10.1007/s11096-022-01395-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-022-01395-7

Keywords

Search

Navigation